News coverage about Iqvia (NYSE:IQV) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Iqvia earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 47.1138991658797 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- William Blair Analysts Reduce Earnings Estimates for Iqvia Holdings Inc (IQV) (americanbankingnews.com)
- Iqvia Holdings Inc (IQV): Why RiverPark Loves This Health Care Services Company (feedproxy.google.com)
- Royal Bank of Canada Analysts Give Iqvia (IQV) a $118.00 Price Target (americanbankingnews.com)
- Analysts Issue Forecasts for Iqvia Holdings Inc’s Q1 2019 Earnings (IQV) (americanbankingnews.com)
- Research Analysts Set Expectations for Iqvia Holdings Inc’s Q2 2018 Earnings (IQV) (americanbankingnews.com)
IQV has been the topic of several recent research reports. Mitsubishi UFJ Financial Group initiated coverage on Iqvia in a research report on Friday, December 15th. They issued a “neutral” rating and a $112.00 price target on the stock. KeyCorp restated a “sector weight” rating and issued a $100.00 price target on shares of Iqvia in a research report on Friday, November 10th. Morgan Stanley raised their price target on Iqvia from $96.00 to $121.00 and gave the stock an “overweight” rating in a research report on Thursday, November 9th. Barclays raised their price target on Iqvia from $100.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, October 27th. Finally, Zacks Investment Research upgraded Iqvia from a “hold” rating to a “buy” rating and set a $121.00 price target on the stock in a research report on Tuesday, October 31st. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $110.02.
Iqvia (NYSE IQV) traded down $1.46 during mid-day trading on Tuesday, reaching $100.26. The company’s stock had a trading volume of 1,301,499 shares, compared to its average volume of 1,200,000. The company has a current ratio of 1.19, a quick ratio of 1.22 and a debt-to-equity ratio of 1.21. The company has a market capitalization of $20,850.00, a price-to-earnings ratio of 66.84, a PEG ratio of 1.81 and a beta of 0.61. Iqvia has a 52-week low of $75.94 and a 52-week high of $110.67.
Iqvia (NYSE:IQV) last posted its earnings results on Wednesday, February 14th. The medical research company reported $1.32 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.34 by ($0.02). The business had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.14 billion. Iqvia had a return on equity of 13.03% and a net margin of 13.44%. The business’s revenue was up 10.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.09 earnings per share. sell-side analysts expect that Iqvia will post 4.1 earnings per share for the current year.
In other Iqvia news, insider Ari Bousbib sold 46,080 shares of Iqvia stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $101.79, for a total value of $4,690,483.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director John Connaughton sold 1,163,191 shares of Iqvia stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $102.00, for a total value of $118,645,482.00. The disclosure for this sale can be found here. Insiders sold a total of 8,727,078 shares of company stock worth $890,124,079 in the last three months. Company insiders own 6.40% of the company’s stock.
WARNING: “Iqvia (IQV) Earns Daily Media Sentiment Score of 0.13” was posted by Stock Observer and is the property of of Stock Observer. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.thestockobserver.com/2018/02/20/iqvia-iqv-earns-daily-media-sentiment-score-of-0-13.html.
Iqvia Company Profile
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.